Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results
Lower Efficacy In Older Adults
Executive Summary
Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.
You may also be interested in...
Novavax Readies COVID-19 Vaccine Request For EUA, But How Much Longer Will The Door Be Open?
Availability of emergency authorization route in US depends upon lack of 'adequate, approved and available alternatives,' but as more vaccines make their way through the BLA process sponsors may find the EUA door slowly closing.
Eye On Delta, Sanofi/GSK To Begin India Trials Of COVID-19 Vaccine
Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant.
GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.